Your browser doesn't support javascript.
loading
CCMG practice guideline: laboratory guidelines for next-generation sequencing.
Hume, Stacey; Nelson, Tanya N; Speevak, Marsha; McCready, Elizabeth; Agatep, Ron; Feilotter, Harriet; Parboosingh, Jillian; Stavropoulos, Dimitri J; Taylor, Sherryl; Stockley, Tracy L.
Afiliación
  • Hume S; Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada.
  • Nelson TN; Department of Pathology and Laboratory Medicine, BC Children's Hospital, Vancouver, British Columbia, Canada.
  • Speevak M; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • McCready E; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
  • Agatep R; Department of Laboratory Medicine and Genetics, Trillium Health Partners, Mississauga, Ontario, Canada.
  • Feilotter H; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Parboosingh J; Department of Biochemistry and Molecular Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Stavropoulos DJ; Genomics Laboratory, Shared Health Diagnostic Services, Winnipeg, Manitoba, Canada.
  • Taylor S; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
  • Stockley TL; Department of Medical Genetics, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
J Med Genet ; 56(12): 792-800, 2019 12.
Article en En | MEDLINE | ID: mdl-31300550
ABSTRACT
PurposeThe purpose of this document is to provide guidance for the use of next-generation sequencing (NGS, also known as massively parallel sequencing or MPS) in Canadian clinical genetic laboratories for detection of genetic variants in genomic DNA and mitochondrial DNA for inherited disorders, as well as somatic variants in tumour DNA for acquired cancers. They are intended for Canadian clinical laboratories engaged in developing, validating and using NGS methods. METHODS OF STATEMENT DEVELOPMENT The document was drafted by the Canadian College of Medical Geneticists (CCMG) Ad Hoc Working Group on NGS Guidelines to make recommendations relevant to NGS. The statement was circulated for comment to the CCMG Laboratory Practice and Clinical Practice committees, and to the CCMG membership. Following incorporation of feedback, the document was approved by the CCMG Board of Directors. DISCLAIMER The CCMG is a Canadian organisation responsible for certifying medical geneticists and clinical laboratory geneticists, and for establishing professional and ethical standards for clinical genetics services in Canada. The current CCMG Practice Guidelines were developed as a resource for clinical laboratories in Canada and should not be considered to be inclusive of all information laboratories should consider in the validation and use of NGS for a clinical laboratory service.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Guías como Asunto / Secuenciación de Nucleótidos de Alto Rendimiento / Genética Médica Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Med Genet Año: 2019 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Guías como Asunto / Secuenciación de Nucleótidos de Alto Rendimiento / Genética Médica Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Med Genet Año: 2019 Tipo del documento: Article País de afiliación: Canadá